Business
Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
CAMBRIDGE, Mass., February 26, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8 - 11, 2026, in Orlando, Florida.
About this update from Sarepta Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":426,"url":"https://media.zenfs.com/en/business-wire.com/c6a0dd57c5f478bd8292fd1b5438cb3a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2fPCobXi1aVfQYW2qF5kAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTg1MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c6a0dd57c5f478bd8292fd1b5438cb3a","width":480,"height":426}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Several abstracts, including a late-breaking podium presentation and posters, bring forward accumulating long-term efficacy, safety and caregiver-reported insights that deepen understanding of dystrophin restoration and its impact in Duchenne","length":242,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":242,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., February 26, 2026--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8 - 11, 2026, in Orlando, Florida.","length":304,"tagName":"p"},{"type":"text","content":"At MDA 2026, Sarepta will present new and ongoing evidence across its rare neuromuscular portfolio, including commercially available gene therapy and exon-skipping treatments in Duchenne muscular dystrophy. Presentations include a late-breaking oral presentation on delandistrogene moxeparvovec gene therapy from the Phase 3 EMBARK study (Part 1) up to three years post-infusion compared with a matched external control. Another abstract will feature caregiver-reported impressions from the Phase 3 EMBARK study through two years of follow-up, offering complementary perspectives on treatment impact beyond clinician-reported and performance-based outcomes. Additionally, a safety analysis of several delandistrogene moxeparvovec clinical studies with up to 7.5 years of patient follow-up will be presented; pooled data will include treatment-related adverse events that most commonly occurred within the first 60 days post-infusion.","length":933,"tagName":"p"},{"type":"text","content":"Sarepta will also present data from across its exon skipping franchise, including Phase 3 results from ES...